Icagen has announced that a safety, pharmacokinetics and pharmacodynamics study of ICA-17043 in pediatric sickle cell disease patients has been initiated. The pediatric study will be an open label, parallel group trial involving a total of 28 patients, ages six to 16, and will be conducted at up to eight academic medical centers across the U.S.

Patients will receive study medication according to one of three dosing schedules over a period of 21 days. The objective of this study is to evaluate the pharmacokinetics, pharmacodynamics and tolerability of ICA-17043 in pediatric patients with sickle cell disease. The data from this study will be used to select doses for subsequent clinical evaluations of the safety and efficacy of ICA-17043 in pediatric subjects. Pediatric patients comprise a significant portion of patients with sickle cell disease.